News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
862,216 Results
Type
Article (87508)
Company Profile (807)
Press Release (773879)
Multimedia
Podcasts (177)
Webinars (28)
Section
Business (233087)
Career Advice (4140)
Deals (39804)
Drug Delivery (139)
Drug Development (91273)
Employer Resources (203)
FDA (18293)
Job Trends (17406)
News (397465)
Policy (39927)
Tag
Academia (3005)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (128)
Alliances (56980)
ALS (147)
Alzheimer's disease (1689)
Antibody-drug conjugate (ADC) (261)
Approvals (18328)
Artificial intelligence (508)
Autoimmune disease (98)
Automation (29)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (167)
Biotechnology (485)
Bladder cancer (138)
Brain cancer (53)
Breast cancer (519)
Cancer (4108)
Cardiovascular disease (356)
Career advice (3562)
Career pathing (38)
CAR-T (252)
CDC (57)
Cell therapy (702)
Cervical cancer (33)
Clinical research (75727)
Collaboration (1435)
Company closure (4)
Compensation (944)
Complete response letters (61)
COVID-19 (2962)
CRISPR (84)
C-suite (612)
Cystic fibrosis (140)
Data (4782)
Decentralized trials (2)
Denatured (64)
Depression (112)
Diabetes (460)
Diagnostics (7101)
Digital health (37)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (242)
Drug pricing (195)
Drug shortages (36)
Duchenne muscular dystrophy (205)
Earnings (99075)
Editorial (54)
Employer branding (25)
Employer resources (172)
Events (133292)
Executive appointments (997)
FDA (20856)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1294)
Gene editing (177)
Generative AI (52)
Gene therapy (561)
GLP-1 (1031)
Government (5391)
Grass and pollen (8)
Guidances (371)
Healthcare (20938)
HIV (49)
Huntington's disease (40)
IgA nephropathy (64)
Immunology and inflammation (252)
Immuno-oncology (22)
Indications (58)
Infectious disease (3212)
Inflammatory bowel disease (191)
Inflation Reduction Act (16)
Influenza (102)
Intellectual property (196)
Interviews (816)
IPO (17931)
IRA (59)
Job creations (5197)
Job search strategy (2866)
Kidney cancer (17)
Labor market (81)
Layoffs (643)
Leadership (37)
Legal (10148)
Liver cancer (92)
Longevity (13)
Lung cancer (590)
Lymphoma (271)
Machine learning (32)
Management (66)
Manufacturing (664)
MASH (145)
Medical device (14900)
Medtech (14925)
Mergers & acquisitions (22774)
Metabolic disorders (1179)
Multiple sclerosis (140)
NASH (23)
Neurodegenerative disease (235)
Neuropsychiatric disorders (63)
Neuroscience (2750)
NextGen: Class of 2025 (7687)
Non-profit (5096)
Now hiring (60)
Obesity (569)
Opinion (315)
Ovarian cancer (140)
Pain (170)
Pancreatic cancer (176)
Parkinson's disease (244)
Partnered (31)
Patents (427)
Patient recruitment (333)
Peanut (57)
People (66328)
Pharmaceutical (145)
Pharmacy benefit managers (29)
Phase I (23356)
Phase II (32855)
Phase III (24784)
Pipeline (2809)
Policy (300)
Postmarket research (3554)
Preclinical (10541)
Press Release (72)
Prostate cancer (204)
Psychedelics (52)
Radiopharmaceuticals (282)
Rare diseases (696)
Real estate (7422)
Recruiting (79)
Regulatory (28105)
Reports (65)
Research institute (2694)
Resumes & cover letters (651)
Rett syndrome (16)
RNA editing (15)
RSV (76)
Schizophrenia (140)
Series A (213)
Series B (159)
Service/supplier (30)
Sickle cell disease (81)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (41)
Startups (4319)
State (2)
Stomach cancer (17)
Supply chain (103)
Tariffs (96)
The Weekly (111)
Vaccines (1059)
Venture capital (67)
Weight loss (402)
Women's health (60)
Worklife (21)
Date
Today (174)
Last 7 days (806)
Last 30 days (2950)
Last 365 days (33548)
2025 (27752)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1282)
Alabama (80)
Alaska (7)
Arizona (307)
Arkansas (14)
Asia (51050)
Australia (8975)
California (9735)
Canada (2916)
China (937)
Colorado (411)
Connecticut (432)
Delaware (279)
Europe (117302)
Florida (1433)
Georgia (321)
Hawaii (3)
Idaho (67)
Illinois (824)
India (55)
Indiana (481)
Iowa (20)
Japan (335)
Kansas (126)
Kentucky (39)
Louisiana (22)
Maine (78)
Maryland (1303)
Massachusetts (7285)
Michigan (318)
Minnesota (577)
Mississippi (4)
Missouri (124)
Montana (33)
Nebraska (26)
Nevada (109)
New Hampshire (80)
New Jersey (2703)
New Mexico (32)
New York (2636)
North Carolina (1428)
North Dakota (10)
Northern California (4453)
Ohio (308)
Oklahoma (22)
Oregon (51)
Pennsylvania (2017)
Puerto Rico (20)
Rhode Island (46)
South America (1655)
South Carolina (51)
South Dakota (1)
Southern California (3713)
Tennessee (152)
Texas (1533)
United States (35857)
Utah (292)
Virginia (253)
Washington D.C. (84)
Washington State (835)
West Virginia (4)
Wisconsin (99)
Wyoming (1)
There are 862,216 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Gilead Still Hungry For Deals as HIV Portfolio Grows, Veklury Crashes
Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, including liver disease, cancer and immunology.
October 31, 2025
·
2 min read
·
Tristan Manalac
IPO
Evommune Joins IPO Class With Planned $160M Raise For Immuno Pipeline
With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to come into effect after a certain window has passed.
October 31, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Syndax Announces Participation in November 2025 Investor Conferences
October 31, 2025
·
1 min read
Press Releases
Nurix Therapeutics to Participate in Upcoming November 2025 Investor Conferences
October 31, 2025
·
2 min read
Press Releases
Metsera Receives Unsolicited Proposal from Novo Nordisk
October 31, 2025
·
10 min read
Press Releases
ELAHERE® Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
October 31, 2025
·
5 min read
Press Releases
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
October 31, 2025
·
6 min read
Press Releases
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
October 31, 2025
·
20 min read
Press Releases
Libtayo® (cemiplimab for injection) Now Reimbursed in Seven Provinces for Advanced Non-Small Cell Lung Cancer and Locally Advanced Basal Cell Carcinoma
October 31, 2025
·
7 min read
Press Releases
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
October 31, 2025
·
5 min read
1 of 86,222
Next
